Direkt zum Inhalt
Merck

Pediatric super-refractory status epilepticus treated with allopregnanolone.

Annals of neurology (2014-11-05)
Eileen Broomall, JoAnne E Natale, Michele Grimason, Joshua Goldstein, Craig M Smith, Celia Chang, Stephen Kanes, Michael A Rogawski, Mark S Wainwright
ZUSAMMENFASSUNG

Super-refractory status epilepticus is a life-threatening condition. Resistance to benzodiazepine and barbiturate treatment for this disorder is thought to be due to internalization of synaptic γ-aminobutyric acid (GABA)A receptors, and withdrawal of benzodiazepines and barbiturates during treatment often triggers seizure recurrence. The neurosteroid allopregnanolone acts as a positive allosteric modulator of synaptic and extrasynaptic GABAA receptors. Here we describe the use of allopregnanolone in 2 pediatric patients with super-refractory status epilepticus. This treatment allowed the general anesthetic infusions to be weaned with resolution of status epilepticus. This is the first report of allopregnanolone use to treat status epilepticus in children.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Supelco
Levetiracetam, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Levetiracetam, ≥98% (HPLC)
Sigma-Aldrich
5,5-Diphenylhydantoin, ≥98%
Supelco
Phenytoin, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
5α-Pregnan-3α-ol-20-one, solid
USP
Phenytoin, United States Pharmacopeia (USP) Reference Standard
USP
Levetiracetam, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
5β-Pregnan-3α-ol-20-one
Phenytoin, European Pharmacopoeia (EP) Reference Standard
Levetiracetam, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Felbamat
Phenytoin für die Systemeignung, European Pharmacopoeia (EP) Reference Standard